Research programme: glucose metabolism therapeutics - XOMA

Drug Profile

Research programme: glucose metabolism therapeutics - XOMA

Alternative Names: Insulin receptor-regulating antibodies - XOMA; X 129; XMet program; XMetA; XMetD; XMetD antibody fragment (Fab); XMetS; XOMA-129

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator XOMA
  • Class Antihypoglycaemics; Monoclonal antibodies
  • Mechanism of Action Insulin receptor agonists; Insulin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Type 1 diabetes mellitus; Type 2 diabetes mellitus

Highest Development Phases

  • Preclinical Hypoglycaemia
  • No development reported Diabetes mellitus

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA (Parenteral)
  • 01 Apr 2017 Pharmacodynamics data from preclinical studies in Hypoglycaemia presented at the 99th Annual Meeting of the Endocrine Society (ENDO-2017)
  • 04 Apr 2016 Pharmacodynamics data from a preclinical trial in Diabetes mellitus released by XOMA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top